Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS5132 Combination Therapy in Advanced Solid Tumors
NCT07453394Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, open-label trial of QLS5132 in gastric cancer (GC), non-small cell lung cancer (NSCLC), endometrial cancer (EC) and 2 more (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Incidence and severity of adverse events at 2 years, Maximum tolerated dose at 28 days and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
QLS5132
03
Conditions
gastric cancer (GC)non-small cell lung cancer (NSCLC)endometrial cancer (EC)solid tumor (advanced stage)ovarian cancer
Beyond the preview
Go deeper on NCT07453394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07453394.